What Are Mitochondrial Disorders?
Mitochondrial disorders are a group of genetic conditions caused by impairment of the respiratory chain involved in generating ATP through oxidative phosphorylation, representing a biochemically and clinically diverse spectrum that can affect any organ system. 1
Definition and Pathophysiology
Mitochondrial disorders result from defects in oxidative phosphorylation (OXPHOS), the common final pathway of mitochondrial energy metabolism. 2 These conditions arise from mutations affecting the respiratory chain complexes embedded in the inner mitochondrial membrane. 1
Key metabolic functions disrupted include: 1
- ATP generation via aerobic respiration
- Tricarboxylic acid (TCA) cycle
- Urea cycle
- β-fatty acid oxidation
- Lipid and cholesterol synthesis
Genetic Basis
The genetic complexity of mitochondrial disorders stems from dual genomic control of the respiratory chain: 1
Nuclear DNA mutations:
- Encode the majority of respiratory complex proteins
- Inherited in autosomal recessive, dominant, or X-linked patterns
- Account for most mitochondrial proteins involved in electron transport 1, 2
Mitochondrial DNA (mtDNA) mutations:
- Each mitochondrion contains multiple copies of circular, double-stranded mtDNA
- Maternally inherited
- Show marked phenotypic heterogeneity 1
Critical genetic concepts: 1
- Homoplasmy: All mitochondria affected
- Heteroplasmy: Only a portion of mitochondria affected
- The percentage of mutant mtDNA load directly contributes to disease expression and severity
Clinical Presentation
Organs with high energy requirements are particularly vulnerable: 1
- Brain
- Skeletal muscle
- Liver
- Heart
- Kidney
When to Suspect Mitochondrial Disease
Consider mitochondrial disorders in these scenarios: 1
- Unexplained constellation of signs with progressive course involving seemingly unrelated organs or tissues
- Clinical presentations at any age (neonatal to adult)
- Specific recognized syndromes
- Multisystem involvement without clear alternative diagnosis
Clinical Spectrum
The phenotypic presentation ranges from: 3, 2
- Single tissue involvement (e.g., Leber's hereditary optic neuropathy affecting only the optic nerve)
- Widespread pathologies including myopathies, peripheral neuropathies, encephalomyopathies, and cardiopathies
- Complex multisystem disorders affecting heart, endocrine system, liver, kidney, blood, and gastrointestinal tract
Common manifestations include: 4
- Global developmental delay
- Cognitive impairment
- Short stature
- Muscular hypotonia
- Progressive neurological decline
Epidemiology and Diagnosis
Mitochondrial diseases represent the most common group of inherited metabolic disorders and are among the most common forms of inherited neurological disorders. 5
Diagnostic advances: 5
- Next-generation sequencing techniques have substantially improved diagnosis, particularly in children
- Modified Walker diagnostic criteria provide structured approach using clinical, histology, enzymology, functional, and molecular parameters 1
Important Clinical Considerations
Phenotypic variability is a major challenge: 5, 6
- Marked clinical variation between patients can delay diagnosis
- The same mutation can produce vastly different clinical presentations
- Severity depends on: DNA mutation severity, proportion of mitochondria affected, tissue susceptibility, and degree of impaired energy metabolism 1
Genetic counseling is essential: 1
- Establishing genetic diagnosis allows reproductive options
- More challenging for women with pathogenic mtDNA mutations (strictly maternally inherited)
- Mitochondrial donation techniques offer future reproductive choices 5
Management Approach
Treatment remains challenging with limited curative options: 5, 7
- Guidelines available to manage disease complications
- Expected outcome is slowing disease progression and clinical stabilization 7
- Therapeutic approaches include electron acceptors, enzyme activators, vitamins, coenzymes, free-radical scavengers, and dietary measures 7
- Special attention to primary deficiencies of L-carnitine, coenzyme Q10, and cofactor-responsive enzyme defects, as supplementation may be curative 7
Clinical trials are in progress with development of large patient cohorts and biomarkers. 5